Filing Details

Accession Number:
0001387131-22-001711
Form Type:
13D Filing
Publication Date:
2022-02-10 19:00:00
Filed By:
Atlas Venture Fund X, L.p.
Company:
Ikena Oncology Inc.
Filing Date:
2022-02-11
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
ATLAS VENTURE FUND X 0 2,901,609 0 2,901,609 2,901,609 8.1%
ATLAS VENTURE ASSOCIATES X 0 2,901,609 0 2,901,609 2,901,609 8.1%
Atlas Venture Associates X 0 2,901,609 0 2,901,609 2,901,609 8.1%
ATLAS VENTURE FUND XI 0 1,241,935 0 1,241,935 1,241,935 3.5%
ATLAS VENTURE ASSOCIATES XI 0 1,241,935 0 1,241,935 1,241,935 3.5%
Atlas Venture Associates XI 0 1,241,935 0 1,241,935 1,241,935 3.5%
Atlas Venture Opportunity Fund I 0 874,634 0 874,634 874,634 2.4%
Atlas Venture Associates Opportunity I 0 874,634 0 874,634 874,634 2.4%
Atlas Venture Associates Opportunity I 0 874,634 0 874,634 874,634 2.4%
Filing

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No. )*

 

IKENA ONCOLOGY, INC.

(Name of Issuer)

 

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

 

45175G108

(CUSIP Number)

 

Atlas Venture

Attention: Ommer Chohan, Chief Financial Officer

300 Technology Square, 8th Floor

Cambridge, MA 02139 USA

(857) 201-2700

(Name, Address and Telephone Number of Person Authorized to

Receive Notices and Communications)

 

March 30, 2021

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.